1331 The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Eitemau Tebyg

• Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials
  gan: Lodise, Thomas P., et al.
  Cyhoeddwyd: (2017)
• Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies
  gan: Corey, G. Ralph, et al.
  Cyhoeddwyd: (2018)
• 675 Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program
  gan: Puttagunta, Sailaja, et al.
  Cyhoeddwyd: (2014)
• 266 Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies
  gan: Puttagunta, Sailaja, et al.
  Cyhoeddwyd: (2014)
• Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting
  gan: Deck, Daniel H., et al.
  Cyhoeddwyd: (2016)